300149 睿智医药
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-1.4191.077-17.089-48.47716.827
总资产报酬率 ROA (%)-0.8920.666-10.224-29.3729.037
投入资产回报率 ROIC (%)-1.0070.748-11.502-32.93910.070

边际利润分析
销售毛利率 (%)22.14628.61521.80025.93525.423
营业利润率 (%)-8.7432.035-22.350-82.25556.350
息税前利润/营业总收入 (%)-5.8242.248-23.476-81.32255.826
净利润/营业总收入 (%)-6.7601.194-23.347-80.54927.320

收益指标分析
经营活动净收益/利润总额(%)97.229113.54226.5216.392-11.315
价值变动净收益/利润总额(%)0.49575.911-3.3650.098190.871
营业外收支净额/利润总额(%)0.522-44.1866.3920.362-2.575

偿债能力分析
流动比率 (X)2.1342.1521.8581.7041.749
速动比率 (X)2.0892.1261.8251.6391.691
资产负债率 (%)35.71536.03637.96739.98837.762
带息债务/全部投入资本 (%)10.13510.27310.54610.32915.544
股东权益/带息债务 (%)705.134686.166648.516643.036443.387
股东权益/负债合计 (%)175.976174.180160.194147.585163.121
利息保障倍数 (X)-1.9642.687-58.773-66.00862.684

营运能力分析
应收账款周转天数 (天)79.09864.40081.73895.71891.814
存货周转天数 (天)5.6454.6479.32915.09420.310